Solid Biosciences (SLDB) Common Equity (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Common Equity data on file, last reported at $374.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 27.06% year-over-year to $374.1 million; the trailing twelve-month figure through Mar 2026 stood at $374.1 million (up 27.06% YoY), and the FY2025 full-year result was $180.0 million, up 31.16% from the prior year.
• Common Equity advanced to $374.1 million in Q1 2026, from $180.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $374.1 million in Q1 2026 to a low of $126.5 million in Q4 2023.
• A 5-year average of $197.3 million and a median of $183.8 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 40.25% in 2023 and surged 39.74% in 2025, its largest moves.
• Tracing SLDB's Common Equity over 5 years: stood at $211.7 million in 2022, then slumped by 40.25% to $126.5 million in 2023, then gained by 8.51% to $137.2 million in 2024, then jumped by 31.16% to $180.0 million in 2025, then jumped by 107.84% to $374.1 million in 2026.
• Business Quant data shows SLDB's Common Equity at $374.1 million in Q1 2026, $180.0 million in Q4 2025, and $217.9 million in Q3 2025.